DrugCendR Australia

Lisata Therapeutics Australia, formerly known as DrugCendR Australia, is a clinical-stage biotechnology company operating as a wholly-owned subsidiary of Lisata Therapeutics. The company was originally established to manage the Australian clinical development operations for Cend Therapeutics' proprietary CendR platform. Its primary focus is the advancement of certepetide (formerly CEND-1 or LSTA1), an investigational tumor-penetrating cyclic peptide designed to modify the solid tumor microenvironment. By targeting alpha-V integrins and neuropilin-1, certepetide activates a tumor-specific transcellular transport pathway that enhances the delivery and efficacy of co-administered anti-cancer therapies. The company's clinical pipeline includes programs evaluating certepetide in combination with standard chemotherapies for advanced solid tumors, including a Phase 2b trial for metastatic pancreatic ductal adenocarcinoma conducted in collaboration with regional clinical trial groups.